-
1
-
-
0342905433
-
Risks of leukaemia and solid tumours in individuals with Down's syndrome
-
Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000; 355 165-169.
-
(2000)
Lancet
, vol.355
, pp. 165-169
-
-
Hasle, H.1
Clemmensen, I.H.2
Mikkelsen, M.3
-
2
-
-
0035412104
-
Pattern of malignant disorders in individuals with Down's syndrome
-
Hasle H. Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol 2001; 2: 429-436.
-
(2001)
Lancet Oncol
, vol.2
, pp. 429-436
-
-
Hasle, H.1
-
3
-
-
11144242549
-
Origins of leukaemia in children with Down syndrome
-
Hitzler JK, Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer 2005; 5: 11-20.
-
(2005)
Nat Rev Cancer
, vol.5
, pp. 11-20
-
-
Hitzler, J.K.1
Zipursky, A.2
-
4
-
-
27744567768
-
Optimizing therapy for myeloid disorders of Down syndrome
-
Webb DK. Optimizing therapy for myeloid disorders of Down syndrome. Br J Haematol 2005; 131: 3-7.
-
(2005)
Br J Haematol
, vol.131
, pp. 3-7
-
-
Webb, D.K.1
-
5
-
-
33646676254
-
Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: Data from 56 children treated on NOPHO-AML protocols and a review of the literature
-
Abildgaard L, Ellebæk E, Gustafsson G, Abrahamsson J, Hovi L, Jonmundsson G et al. Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: Data from 56 children treated on NOPHO-AML protocols and a review of the literature. Ann Hematol 2006; 85: 275-280.
-
(2006)
Ann Hematol
, vol.85
, pp. 275-280
-
-
Abildgaard, L.1
Ellebæk, E.2
Gustafsson, G.3
Abrahamsson, J.4
Hovi, L.5
Jonmundsson, G.6
-
6
-
-
33644905562
-
Treatment for myeloid leukaemia of Down syndrome: Population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials
-
Rao A, Hills RK, Stiller C, Gibson BE, De Graaf SS, Hann IM et al. Treatment for myeloid leukaemia of Down syndrome: Population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. Br J Haematol 2006; 132: 576-583.
-
(2006)
Br J Haematol
, vol.132
, pp. 576-583
-
-
Rao, A.1
Hills, R.K.2
Stiller, C.3
Gibson, B.E.4
De Graaf, S.S.5
Hann, I.M.6
-
7
-
-
0037325661
-
A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases
-
Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003; 17: 277-282.
-
(2003)
Leukemia
, vol.17
, pp. 277-282
-
-
Hasle, H.1
Niemeyer, C.M.2
Chessells, J.M.3
Baumann, I.4
Bennett, J.M.5
Kerndrup, G.6
-
8
-
-
0142089730
-
Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloidleukemia: A report from the Children's cancer group Study 2891
-
Gamis AS, Woods WG, Alonzo TA, Buxton A, Lange B, Barnard DR et al Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloidleukemia: A report from the Children's cancer group Study 2891. J Clin Oncol 2003; 21: 3415-3422.
-
(2003)
J Clin Oncol
, vol.21
, pp. 3415-3422
-
-
Gamis, A.S.1
Woods, W.G.2
Alonzo, T.A.3
Buxton, A.4
Lange, B.5
Barnard, D.R.6
-
9
-
-
18944404989
-
AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity
-
Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 2005; 19: 1355-1360.
-
(2005)
Leukemia
, vol.19
, pp. 1355-1360
-
-
Creutzig, U.1
Reinhardt, D.2
Diekamp, S.3
Dworzak, M.4
Stary, J.5
Zimmermann, M.6
-
10
-
-
16744366910
-
Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's cancer group studies 2861 and 2891
-
Lange BJ, Kobrinsky N, Barnard DR, Arthur DC, Buckley JD, Howells WB et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's cancer group studies 2861 and 2891. Blood 1998; 91 608-615.
-
(1998)
Blood
, vol.91
, pp. 608-615
-
-
Lange, B.J.1
Kobrinsky, N.2
Barnard, D.R.3
Arthur, D.C.4
Buckley, J.D.5
Howells, W.B.6
-
11
-
-
0031213812
-
Acute myeloblastic leukemia associated with trisomy 8 and translocation 8;21 in a child with Down syndrome
-
Yamaguchi Y, Fujii H, Kazama H, Iinuma K, Shinomiya N, Aoki T. Acute myeloblastic leukemia associated with trisomy 8 and translocation 8;21 in a child with Down syndrome. Cancer Genet Cytogenet 1997; 97 32-34.
-
(1997)
Cancer Genet Cytogenet
, vol.97
, pp. 32-34
-
-
Yamaguchi, Y.1
Fujii, H.2
Kazama, H.3
Iinuma, K.4
Shinomiya, N.5
Aoki, T.6
-
12
-
-
8044248968
-
Acute myelogenous leukaemia with t(8;21) translocation of normal cell origin in mosaic Down's syndrome with isochromosome 21 q
-
Sato A, Imaizumi M, Koizumi Y, Obara Y, Nakai H, Noro T et al. Acute myelogenous leukaemia with t(8;21) translocation of normal cell origin in mosaic Down's syndrome with isochromosome 21 q. Br J Haematol 1997; 96: 614-616.
-
(1997)
Br J Haematol
, vol.96
, pp. 614-616
-
-
Sato, A.1
Imaizumi, M.2
Koizumi, Y.3
Obara, Y.4
Nakai, H.5
Noro, T.6
-
13
-
-
33644780833
-
Acute promyelocytic leukemia and constitutional trisomy 21
-
Kurkjian C, Patel S, Kamble R, Dunn ST, Kern W, Kharfan-Dabaja MA. Acute promyelocytic leukemia and constitutional trisomy 21. Cancer Genet Cytogenet 2006; 165: 176-179.
-
(2006)
Cancer Genet Cytogenet
, vol.165
, pp. 176-179
-
-
Kurkjian, C.1
Patel, S.2
Kamble, R.3
Dunn, S.T.4
Kern, W.5
Kharfan-Dabaja, M.A.6
-
14
-
-
12144287045
-
Natural history of GATA1 mutations in Down syndrome
-
Ahmed M, Sternberg A, Hall G, Thomas A, Smith O, O'Marcaigh A et al Natural history of GATA1 mutations in Down syndrome. Blood 2004; 103: 2480-2489.
-
(2004)
Blood
, vol.103
, pp. 2480-2489
-
-
Ahmed, M.1
Sternberg, A.2
Hall, G.3
Thomas, A.4
Smith, O.5
O'Marcaigh, A.6
-
15
-
-
20044381309
-
Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1
-
Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet 2005; 37: 613-619.
-
(2005)
Nat Genet
, vol.37
, pp. 613-619
-
-
Li, Z.1
Godinho, F.J.2
Klusmann, J.H.3
Garriga-Canut, M.4
Yu, C.5
Orkin, S.H.6
|